RT Journal Article
SR Electronic
T1 Measuring inflammation in paediatric severe asthma: biomarkers in clinical practice
JF Breathe
JO Breathe
FD European Respiratory Society
SP 190301
DO 10.1183/20734735.0301-2019
VO 16
IS 1
A1 Amelia Licari
A1 Sara Manti
A1 Riccardo Castagnoli
A1 Salvatore Leonardi
A1 Gian Luigi Marseglia
YR 2020
UL http://breathe.ersjournals.com/content/16/1/190301.abstract
AB Severe asthma in children is a highly heterogeneous disorder, encompassing different clinical characteristics (phenotypes) and immunopathological pathways (endotypes). Research is focusing on the identification of noninvasive biomarkers able to predict treatment response and assist in designing personalised therapies for severe asthma. Blood and sputum eosinophils, serum IgE and exhaled nitric oxide fraction mostly reflect type 2 airway inflammation in children. However, in the absence of available point-of-care biomarkers, the diagnosis of non-type 2 asthma is still reached by exclusion. In this review, we present the most recent evidence on biomarkers for severe asthma and discuss their implementation in clinical practice. We address the methods for guiding treatment decisions and patient identification, focusing on the paediatric age group.Key pointsSevere asthma in children is a highly heterogeneous disorder, encompassing different clinical characteristics (phenotypes) and immunopathological pathways (endotypes).Research is focusing on the identification of noninvasive biomarkers able to predict treatment response and assist in designing personalised therapies for severe asthma.Blood and sputum eosinophils, serum IgE and exhaled nitric oxide fraction mostly reflect type 2 airway inflammation in children. However, knowledge regarding non-type 2 inflammation and related biomarkers is still lacking.Educational aimsTo summarise the most recent evidence on biomarkers for severe asthma in children.To discuss their implementation in clinical practice through guiding patient identification and treatment decisions.Noninvasive biomarkers should be integrated with clinical findings to assist in diagnosing and guiding personalised therapies for severe asthma in children http://bit.ly/2JPvKFV